Introduction
Glaucoma is a term used to describe a group of disorders that have in common progressive degeneration of the optic nerve causing visual compromise and eventually blindness. Collectively, glaucoma is the leading cause of irreversible blindness world-wide. Elevated intraocular pressure (IOP) is a major risk factor for most types of glaucoma. Fluid formed by the ciliary body (aqueous humor) is removed by the trabecular meshwork and Schlemm's canal located in the ocular 'angle' that forms at the junction of the cornea and iris (Fig. 1) . The IOP level is dependent on the rate of fluid removal, which is decreased in all types of glaucoma with elevated IOP. Glaucoma subgroups are defined as 'open-angle' or 'closed-angle' depending on the position of the ocular lens and iris relative to the trabecular meshwork ( Fig. 1) . Open angle glaucoma is further divided into subgroups defined by the ocular features that characterize them. For example exfoliation syndrome (XFS) and the related glaucoma (XFG) are defined by the accumulation of a characteristic fibrillar material on the ocular lens and trabecular meshwork (Fig. 2) . Primary open angle glaucoma (POAG), a type of glaucoma defined by anatomically normal structures in the absence of any secondary cause of glaucoma, such as XFS, also includes the normal tension glaucoma (NTG) subgroup patients who develop glaucomatous optic neuropathy in the absence of abnormally elevated IOP.
Glaucoma can occur at all ages, with early onset disease (before the age of 40) exhibiting Mendelian inheritance and adult onset forms (developing after age 40) inherited as complex traits (1) . Generally, mutations in genes causing early onset glaucoma are rare with large biological effects, while variants contributing to the adult-onset glaucomas are common with smaller effects (2). Genome-wide association studies (GWAS) have successfully identified genomic loci for POAG (3) (4) (5) (6) (7) (8) (9) (10) (11) (Table 1) , NTG (5), XFS (12, 13) and PACG (primary angle closure glaucoma) (14, 15) . These advances will be discussed in this review, as well as new information regarding genes responsible for Mendelian forms of open angle glaucoma. While the function of these genes and genomic loci in health and disease are not completely understood, these findings are providing new insights into the underlying molecular mechanisms responsible for glaucoma that could eventually lead to novel gene-based therapies, including strategies for neuroprotection. Additionally, gene-based diagnostic testing for mutations responsible for early-onset Mendelian glaucoma can detect individuals at the earliest stages of disease when therapy is most effective.
Early-Onset Open Angle Glaucoma
Early onset glaucoma with Mendelian inheritance can involve ocular developmental abnormalities that will be covered in another review in this issue (Fingert) . Some types of early onset glaucoma, however, are associated with developmentally normal ocular structures including juvenile open angle glaucoma (JOAG) and familial normal tension glaucoma, to be discussed in the following sections.
Familial normal tension glaucoma (NTG)
Rare mutations involving two genes, an OPTN (optineurin) missense mutation (E50K) and CNVs (copy number variations) involving TBK1 (Tank-binding protein 1), cause early-onset familial NTG with autosomal dominant inheritance (16) (17) (18) (19) (20) . Individuals affected by NTG caused by OPTN and TBK1 mutations develop severe disease prior to age 40 (17, 18) . Together mutations in these two genes account for approximately 2-3% of NTG (20) . OPTN and TBK1 have important roles in critical cellular processes, notably autophagy and NF-jB signaling (20, 21) , and the encoded proteins are known to interact (22, 23) . Optineurin normally negatively regulates NF-jB, a process that is modulated by TBK1 (21) . The E50K OPTN mutation enhances TBK1-OPTN binding (24) potentially increasing NF-jB activity and promoting cell death (25) . Phosphorylation of OPTN by TKB1 also promotes the recruitment of microtubule-associated protein 1 light chain 3 beta (MAP1LC3B, LC3B) an important step in the initiation of autophagy (26) , and this interaction is also being enhanced by the OPTN E50K missense mutation (23, 27) .
Recently, OPTN and TBK1 mutations have been identified in patients with ALS (amyotrophic lateral sclerosis) (28) and another ALS associated protein ATXN2 (29) , has also been associated with POAG (see below) (11) . These results suggest that genes encoding other ALS-related proteins, or proteins involved in autophagy and or NF-jB signaling could also contribute to NTG. However, one such protein, sequestosome (SQSTM1) that encodes an autophagy receptor that is a target of TBK1 phosphorylation, does not appear to contribute to NTG (30) .
Juvenile open angle glaucoma (JOAG)
JOAG is defined as onset of open angle glaucoma before age 40. Typically, patients affected by JOAG develop a severe form of glaucoma characterized by very high IOP that can be difficult to control by current therapies. Existing therapies are most effective at early disease stages, however, patients may be asymptomatic and not seek medical attention early in the disease, limiting the opportunity for early intervention (31) . The identification of genes responsible for JOAG and other early-onset forms of glaucoma would make gene-based diagnostic testing possible, providing for early detection of at-risk individuals before irreversible vision loss occurs.
MYOC (myocilin) mutations are an important cause of JOAG with dominant inheritance (32) . Most disease-causing mutations are missense alleles located in the third exon that codes for the olfactomedin domain (33) . A relatively common nonsense mutation (GLN368X) is associated with the mildest MYOC-related disease (34), while many missense mutations (notably PRO370LEU and TYR347HIS) cause the most severe phenotype. Overall MYOC mutations account for 8-36% of JOAG (35, 36 ) and 2-4% of adult-onset POAG (35,37) depending on the ethnicity of the population. Deletions involving MYOC or nonsense mutations near the N-terminal do not cause disease suggesting that the underlying genetic mechanism is not loss of function but dominant negative or gain of function (38, 39) . Recently MYOC mutations have been shown to cause protein misfolding and protein aggregation causing ER stress (40) . Sodium 4-phenylbutyrate, a molecular chaperone known to relieve the misfolded protein response in urea cycle disorders, also relieved ER stress and lowered IOP in a transgenic MYOC mouse (41, 42) , identifying a new opportunity for novel genebased therapies for MYOC mutation carriers. Since absence of Myocilin does not result in ocular or systemic diseases (38) , other strategies to eliminate or reduce MYOC expression could also be developed as effective therapeutics. 
Common Adult-Onset Glaucoma with Complex Inheritance

Primary open-angle glaucoma
Primary open-angle glaucoma is the most common form of glaucoma in most populations worldwide (43) . Patients with POAG have glaucoma despite anatomically normal ocular structures including open angles. Like other forms of glaucoma, IOP elevation is an important risk factor for POAG, however, up to one-third of POAG patients with optic nerve degeneration have IOP in the normal range, defining the normal tension glaucoma (NTG) POAG subgroup (44) . Patients with NTG may have increased susceptibility to optic nerve degeneration compared to POAG overall (5).
Recent genome-wide association studies (GWAS) completed for POAG and NTG in European Caucasian and Asian populations have identified ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, and TXNRD2 (7-11) bringing the total number of genes/loci significantly associated with disease to 16 ( Table 1) . Several loci have been associated at the genome-wide level in both Asian and European Caucasian populations including CDKN2BAS, SIX6, and ABCA1 (6, 8) . GWAS in African-American or other African populations have not yet been done, an important area of future research considering the high disease prevalence in these populations (43) .
Current SNPs associated with POAG are common (minor allele frequencies > 0.3) and have odds ratios (ORs) ranging from 1.4 (CDKN2BAS, rs7866783; SIX6, rs33912345) to 1.17 (FOXC1, rs2745572 and TXNRD2, rs35934224) (11) . Interestingly, some disease-associated SNPs have stronger evidence for association in specific phenotypic subgroups supporting the genetic and phenotypic heterogeneity of the disease. For example, association of CDKN2BAS SNPs is stronger for NTG compared to POAG overall (OR ¼ 1.6 for NTG compared to 1.4 for POAG overall) (11) and the association of CAV1/CAV2 SNPs is stronger for the POAG subgroup with paracentral visual field loss (OR ¼ 1.57 compared with 1.26 for POAG overall) (45).
POAG associated loci involve diverse biological processes including cytokine signaling (CDKN2BAS, TGFBR2, FNDC3B), lipid metabolism (ABCA1, CAV1/CAV2, ARHGEF12), membrane biology (CAV1/CAV2), extracellular matrix (AFAP1), fucose and mannose metabolism (GMDS, PMM2), cell division (CDKN2BAS, TMCO1, GAS7) and ocular development (SIX6, FOXC1) (2). Several pathways are particularly interesting. Interactions among ABCA1, CAV1/CAV2, and ARHGEF12 can influence lipid and cholesterol metabolism (46, 10) , and recent studies suggest that statin treatment for hypercholesterolemia may be protective for glaucoma (47) . Further studies investigating statin use in individuals with associated risk variants in these loci could reveal clinically relevant pharmacogenetic relationships. Recent studies are also identifying important contributions of mitochondria to glaucoma pathogenesis (48) . TXNRD2, significantly associated with POAG in a recent GWAS (11), codes for thioredoxin reductase 2, a mitochondrial protein necessary for reducing damaging reactive oxygen species generated by oxidative phosphorylation and other mitochondrial functions (49) . The mitochondria-rich retinal ganglion cells damaged in glaucoma are known to be susceptible to oxidative stress (50) suggesting that reduction in reactive oxygen species could be neuroprotective. The importance of mitochondrial function is also evident from gene-set analyses using mitochondrial protein-encoding genes that show an association with POAG and in particular NTG (51).
Primary angle-closure glaucoma (PACG)
PACG is a major cause of irreversible blindness, especially in Asia. Patients with PACG can have acute, subacute or chronic presentations. Regardless of symptoms, PACG patients develop elevated IOP secondary to apposition of the peripheral iris and trabecular meshwork that creates a barrier to fluid flowing out of the eye (Fig. 1) . PACG can result in very high IOP causing optic nerve degeneration (52) .
Various studies suggest that PACG has a genetic component (53-55), however, no environmental risk factors have The reference number in this review is listed in parentheses after the abbreviated reference.
*The discovery analysis for this study was a population-based study for IOP (N ¼ 8105). Replication was done in a second population based analysis of 7471 individuals.
The top SNPs after replication were assessed for association with POAG in 1225 cases and 4117 controls.
been identified. While familial PACG has been reported in Basset Hounds (56) , in humans, familial aggregation of earlyonset angle-closure glaucoma phenotypically is within the spectrum of nanophthalmos, an extreme form of hyperopia that can cause closure of the angles due to age-related enlargement of the lens in the small hyperopic eye. Nanopthalmos can be inherited as an autosomal dominant or recessive trait and mutations in MFRP (57) and TMEM98 (58) have been identified in recessive and dominant forms of the disease, respectively. In addition, there is an autosomal recessive form of retinal degeneration termed bestrophinopathy that is commonly accompanied by angle closure glaucoma and produced by mutations in BEST1 (59).
Genome wide association studies have identified 8 genes/ loci for the common adult-onset form of PACG: PLEKHA7, COL11A1, PCMTD1-ST18, EPDR1, CHAT, GLIS3, FERMT2, and DPM2-FAM102 (14, 15) . These loci were identified in large casecontrol sets mostly from Asia. The effect sizes for these variants are between 1.2-1.4 and only explain <2% of the genetic variance in PACG. None of these PACG loci were associated with primary open-angle glaucoma (POAG) in a Singaporean Chinese sample consisting of 986 cases and 3916 controls while only 2 POAG loci (rs2226035, ARHGEF12 and rs12150284, GAS7) were nominally associated with PACG, suggesting there is little etiological overlap between these two major forms of glaucoma (15) .
Common variants in genes that cause inherited forms of nanophthalmos have been ruled out as candidate genes for the common forms of PACG with complex inheritance. The concept that PACG is directly correlated with eye size is not entirely supported by genomic data, as variants identified for axial length (AxL) in a genome-wide quantitative-linked trait (QLT) analysis (60) were not related to PACG (15) . However, genes that are related to the depth of the anterior chamber (ACD) can be associated with disease. For instance the intergenic PACG susceptibility locus between PCMTD1 and ST18 (rs1015213) was associated with smaller ACD but not AxL in a European sample of 986 subjects (61) . It should be noted that the LD block for rs1015213 includes PCMTD1 but not ST18 and that PCMTD1 is expressed in the anterior segment while ST18 has more limited ocular expression (15) . Furthermore a QLT analysis identified ABCC5 associated with ACD in a dataset consisting 4276 PACG cases and 18,801 controls, this variant was also associated with PACG (OR ¼ 1.13; 95%CI: 1.06-1.22; P ¼ 0.00046) (62) .
Eyes with angle closure glaucoma have a thicker retinal choroid than normal eyes and eyes affected by POAG even after adjusting for AxL (63) , suggesting that cell-cell adhesion in the vascular uveal tract represents an important attribute of PACG. Several PACG genetic loci (EPDR1, FERMT2 and PLEKHA7) are involved in cell adhesion (15) . Interestingly, anticholinergics are known to precipitate acute PACG attacks and one PACG susceptibility locus (CHAT) encodes an enzyme involved in generating acetylcholine (15) implicating acetylcholine metabolism in PACG pathogenesis, and suggesting a potential target for therapeutic prevention in high-risk populations.
Exfoliation syndrome and glaucoma
In exfoliation syndrome (XFS) there is an accumulation of fibrillar material in the anterior ocular segment, most conspicuously at the pupillary margin and on the lens surface (Fig. 2) . These deposits lodge in the trabecular meshwork and contribute to elevated IOP, optic nerve degeneration and glaucoma. Similar deposits with unclear clinical significance have been detected in non-ocular tissues (64) . Overall, XFS appears to be a form of deleterious ocular aging that is also associated with premature cataract formation, cataract surgery complications and retinal venous occlusive disease (65) . The mechanisms underlying formation of the disease-related extracellular deposits remain unknown but the condition appears to have both genetic (66) and environmental components (67) .
There are no familial aggregation or candidate gene studies that have identified significant genetic risk factors for XFS. Remarkably, a genome-wide association study using a discovery set consisting of only 75 unrelated cases and 14,470 populationbased controls from Iceland identified LOXL1 (lysyl oxidase like 1) SNPs (rs3825942; rs1048661 and rs2165241) significantly associated with XFS (12) . The top SNP effect size is amongst the highest observed for common complex disease in the GWAS era (20-fold for rs3825942) and suggests that LOXL1 has an important role in XFS pathogenesis. LOXL1 is involved in elastogenesis and collagen crosslinking which could impact XFS development by modulating extracelluar matrix stability. The co-occurrence of systemic (68, 69) and ocular vasculopathies (70) with XFS, and an association between pelvic organ prolapse and XFS, collectively suggest that LOXL1 maintenance of elastin and collagen is altered in XFS (71) . In European Caucasians and most populations world-wide the disease-associated variants (rs3825942; rs1048661 and rs2165241) are the common alleles present in up to 99% of cases and up to 80% of controls (72) . However, in some Asian and African populations the common variants associated with disease are flipped compared to the European Caucasians (73) . Collectively, these observations suggest that LOXL1 is necessary but not sufficient for disease development and that other genetic variants and also environmental factors are likely to contribute to the disease development.
A second XFS GWAS using meta-analyses of multi-ethnic populations identified CACNA1A as an additional locus for XFS (13) . CACNA1A codes for a P/Q voltage dependent calcium channel. The observation that XFS disease burden does not correlate with LOXL1 risk variant frequencies in world-wide populations (72, 74) also prompted a search for environmental risk factors for the condition. Interestingly multivariable analyses indicated that XFS disease burden increases in extra-equatorial regions (75) and environmental risk factors that could explain this trend were sought. Higher coffee consumption and lower dietary folate intake exhibit these trends and were found to be associated with increased risk of XFS (76) . Furthermore, more time spent outdoors appears to be a strong risk factor for XFS (77) implicating ocular UV exposure, which is known to up-regulate LOXL1 activity (78) . While genetic and environmental studies have shed light on XFS, further research and the identification of additional genetic loci and environmental risk factors will be needed to gain a better understanding of disease pathogenesis.
Conclusion
Genetic and genomic studies are finding important genes contributing to glaucoma. Glaucoma-related genes are beginning to define relevant biological pathways and processes that could be targets for novel gene-based therapies. Gene discovery is also enabling the development of gene-based tests capable of identifying individuals at risk before irreversible blindness occurs. Further research will be required to fully define the genetic architecture of glaucoma, a necessary step before comprehensive genetic testing and targeted gene-based therapy can be achieved.
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